CRANE CO (CR)

US2244081046 - Common Stock

152.91  -0.01 (-0.01%)

After market: 152.91 0 (0%)

Fundamental Rating

6

Overall CR gets a fundamental rating of 6 out of 10. We evaluated CR against 132 industry peers in the Machinery industry. CR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CR has a valuation in line with the averages, but it does not seem to be growing.



7

1. Profitability

1.1 Basic Checks

CR had positive earnings in the past year.
CR had a positive operating cash flow in the past year.
In the past 5 years CR has always been profitable.
CR had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

CR has a better Return On Assets (9.61%) than 78.46% of its industry peers.
CR has a Return On Equity of 16.36%. This is in the better half of the industry: CR outperforms 73.08% of its industry peers.
With a decent Return On Invested Capital value of 10.86%, CR is doing good in the industry, outperforming 73.08% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CR is below the industry average of 11.21%.
The last Return On Invested Capital (10.86%) for CR is above the 3 year average (7.54%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.61%
ROE 16.36%
ROIC 10.86%
ROA(3y)12.5%
ROA(5y)8.89%
ROE(3y)26.74%
ROE(5y)20.22%
ROIC(3y)7.54%
ROIC(5y)7.39%

1.3 Margins

CR's Profit Margin of 10.91% is fine compared to the rest of the industry. CR outperforms 76.92% of its industry peers.
In the last couple of years the Profit Margin of CR has grown nicely.
CR's Operating Margin of 14.90% is fine compared to the rest of the industry. CR outperforms 74.62% of its industry peers.
CR's Operating Margin has been stable in the last couple of years.
CR's Gross Margin of 38.08% is fine compared to the rest of the industry. CR outperforms 71.54% of its industry peers.
CR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 14.9%
PM (TTM) 10.91%
GM 38.08%
OM growth 3Y9.04%
OM growth 5Y-0.57%
PM growth 3Y25.78%
PM growth 5Y4.1%
GM growth 3Y4.04%
GM growth 5Y1.65%

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CR is still creating some value.
Compared to 1 year ago, CR has more shares outstanding
The number of shares outstanding for CR has been reduced compared to 5 years ago.
The debt/assets ratio for CR is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 7.28 indicates that CR is not in any danger for bankruptcy at the moment.
The Altman-Z score of CR (7.28) is better than 88.46% of its industry peers.
The Debt to FCF ratio of CR is 1.98, which is an excellent value as it means it would take CR, only 1.98 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.98, CR belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
A Debt/Equity ratio of 0.26 indicates that CR is not too dependend on debt financing.
CR has a better Debt to Equity ratio (0.26) than 66.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.98
Altman-Z 7.28
ROIC/WACC1.33
WACC8.16%

2.3 Liquidity

CR has a Current Ratio of 2.13. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.13, CR perfoms like the industry average, outperforming 50.77% of the companies in the same industry.
A Quick Ratio of 1.38 indicates that CR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.38, CR perfoms like the industry average, outperforming 59.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.38

3

3. Growth

3.1 Past

CR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.81%.
Measured over the past years, CR shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.15% on average per year.
CR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.76%.
The Revenue has been decreasing by -9.01% on average over the past years.
EPS 1Y (TTM)-29.81%
EPS 3Y13.05%
EPS 5Y-4.15%
EPS Q2Q%18.18%
Revenue 1Y (TTM)-27.76%
Revenue growth 3Y-10.77%
Revenue growth 5Y-9.01%
Sales Q2Q%14.05%

3.2 Future

The Earnings Per Share is expected to grow by 13.34% on average over the next years. This is quite good.
Based on estimates for the next years, CR will show a small growth in Revenue. The Revenue will grow by 6.85% on average per year.
EPS Next Y110.02%
EPS Next 2Y51.95%
EPS Next 3Y13.06%
EPS Next 5Y13.34%
Revenue Next Year75.37%
Revenue Next 2Y35.8%
Revenue Next 3Y6.57%
Revenue Next 5Y6.85%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 34.36, CR can be considered very expensive at the moment.
66.92% of the companies in the same industry are cheaper than CR, based on the Price/Earnings ratio.
CR's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 30.71.
CR is valuated correctly with a Price/Forward Earnings ratio of 15.32.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CR indicates a somewhat cheap valuation: CR is cheaper than 66.92% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.09. CR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 34.36
Fwd PE 15.32

4.2 Price Multiples

67.69% of the companies in the same industry are cheaper than CR, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CR is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 45.97
EV/EBITDA 23.34

4.3 Compensation for Growth

CR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CR has a very decent profitability rating, which may justify a higher PE ratio.
CR's earnings are expected to grow with 13.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y51.95%
EPS Next 3Y13.06%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.53%, CR is not a good candidate for dividend investing.
CR's Dividend Yield is comparable with the industry average which is at 1.76.
With a Dividend Yield of 0.53, CR pays less dividend than the S&P500 average, which is at 2.26.
Industry RankSector Rank
Dividend Yield 0.53%

5.2 History

The dividend of CR is nicely growing with an annual growth rate of 51.53%!
CR has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)51.53%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

18.22% of the earnings are spent on dividend by CR. This is a low number and sustainable payout ratio.
The dividend of CR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP18.22%
EPS Next 2Y51.95%
EPS Next 3Y13.06%

CRANE CO

NYSE:CR (9/16/2024, 8:04:38 PM)

After market: 152.91 0 (0%)

152.91

-0.01 (-0.01%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.75B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 0.53%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 34.36
Fwd PE 15.32
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.31
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.61%
ROE 16.36%
ROCE
ROIC
ROICexc
ROICexgc
OM 14.9%
PM (TTM) 10.91%
GM 38.08%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.13
Quick Ratio 1.38
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-29.81%
EPS 3Y13.05%
EPS 5Y
EPS Q2Q%
EPS Next Y110.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-27.76%
Revenue growth 3Y-10.77%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y